Oral News and Research

RSS

Patients with psoriasis at increased risk for developing diabetes

Study findings suggest that psoriasis is an independent risk factor for the development of Type 2 diabetes.

22 Jun 2012

The health law on the campaign trail

As the White House prepares for the upcoming high court health law ruling, President Barack Obama heads out to speak to Latino leaders. He is likely to speak about the overhaul -- a day after GOP presidential hopeful Mitt Romney pledged that he would do away with it.

22 Jun 2012

First Edition: June 22, 2012

Reporting for Kaiser Health News, Roni Caryn Rabin writes: "They say everything is bigger in Texas, and the problem of the uninsured is no exception. The Houston metropolitan area has one of the highest rates of uninsured people in America, and a health safety net imploding under the demands of too many people and too few resources.

22 Jun 2012

Fructose may not be as bad for us as previously thought

A new study by researchers at St. Michael's Hospital suggests that fructose may not be as bad for us as previously thought and that it may even provide some benefit.

22 Jun 2012

Depomed acquires all rights to Zipsor from Xanodyne

Depomed, Inc. today announced that it has acquired all rights to Zipsor (diclofenac potassium) Liquid Filled Capsules from Xanodyne Pharmaceuticals, Inc. Zipsor is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of mild to moderate acute pain in adults.

22 Jun 2012

Southern Implants, Keystone announce merger agreement

Keystone Dental, Inc., a leading oral healthcare company dedicated to the delivery of breakthrough implant technology, and Southern Implants, Inc., a producer of unique and innovative dental implant technologies aimed to simplify clinical challenges for implant surgeons and restorative dentists, today announced the companies have merged.

From Danaher 22 Jun 2012

Aeterna Zentaris announces perifosine Phase 1 trial on neuroblastoma

Aeterna Zentaris Inc. today announced that Phase 1 trial results for its oral PI3K/Akt inhibitor, perifosine, showed the drug's activity against chemo-resistant and radio-resistant neuroblastoma, while allowing good quality of life and sparing vital organs. Neuroblastoma is a type of childhood cancer which usually begins in nerve tissues.

22 Jun 2012

Iroko announces results from diclofenac Phase 3 study on post-surgical pain

Iroko Pharmaceuticals, LLC today announced Phase 3 study results that showed patients treated with the company's novel, submicron particle, lower-dose diclofenac (18mg and 35mg), a non-steroidal anti-inflammatory drug (NSAID), experienced significant pain relief post surgery compared with placebo>0.01 and P<0.001 respectively).

22 Jun 2012

Cognitive function worse in pediatric BD I than II

Children with bipolar I disorder have significantly poorer cognitive functioning than those with bipolar II disorder, research shows.

21 Jun 2012

Even small-stage oral SCC metastases impact prognosis

The presence of even small tumor-cell deposits in the lymph nodes of patients with early oral and oropharyngeal squamous cell carcinoma reflects a potential for the primary tumor to metastasize, report researchers in Head and Neck.

21 Jun 2012

Poll: Majority want new effort if court overturns health law

A new Associated Press-GfK poll found that Americans want Congress and the president to work on new legislation to overhaul the health care system if the high court rules that the 2010 health law is unconstitutional. Meanwhile, the lead attorney for the states challenging the law said it's difficult to predict what the court will do.

21 Jun 2012

Levodopa/carbidopa intestinal gel reduces 'off' time in people with advanced PD

A new delivery method for levodopa/carbidopa, a common dual-drug Parkinson's disease (PD) regimen, significantly improved the duration of the drugs' effectiveness in people with advanced PD, according to research by Mount Sinai School of Medicine.

21 Jun 2012

Gracilis muscle flap an effective treatment for facial paralysis in patients with NF2

A surgical technique using a muscle flap from the thigh restores facial motion—and the ability to smile—in patients with facial nerve paralysis resulting from neurofibromatosis type 2 (NF2), reports a study in this month's special "Operative Neurosurgery" supplement to Neurosurgery, official journal of the Congress of Neurological Surgeons.

21 Jun 2012

FDA grants Orphan Drug Designation to Medgenics’ INFRADURE Biopump

Medgenics, Inc., the developer of Biopump, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that its INFRADURE Biopump has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for the treatment of hepatitis D.

21 Jun 2012

Review describes new classes of drugs that target androgens in novel ways

Prostate cancer cells require androgens including testosterone to grow. A recent review in the British Journal of Urology International describes new classes of drugs that target androgens in novel ways, providing alternatives to the traditional methods that frequently carry high side effects.

21 Jun 2012

Affordability of diarrhea treatment offers hope for improving child survival

In this post in the Huffington Post's "Global Motherhood" blog, Doug Horswill, senior vice president of the Canadian resource company Teck, and Venkatesh Mannar, president of the Micronutrient Initiative, which works to eliminate vitamin and mineral deficiencies in the world's most vulnerable populations, examine global efforts to end child deaths from diarrhea, a campaign they say "many are calling the next revolution in child survival."

20 Jun 2012

Furiex initiates MuDelta Phase III studies in IBS-D

Furiex Pharmaceuticals, Inc. today announced dosing of the first patient in its Phase III randomized, double-blind, placebo-controlled studies evaluating efficacy, safety and tolerability of MuDelta (JNJ-27018966) in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).

20 Jun 2012

Positive results from Zalicus Z944 Phase 1 SAD clinical study for chronic inflammatory pain

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, announced that it is has successfully completed a Phase 1 single ascending dose (SAD) clinical study with Z944, its novel, oral, T-type calcium channel blocker.

19 Jun 2012

AstraZeneca, Rigel enter global license agreement for R256 inhaled JAK inhibitor to treat chronic asthma

AstraZeneca and Rigel Pharmaceuticals Inc. today announced an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel's inhaled JAK inhibitor shown to inhibit IL-13 and IL-4 signalling, which is being investigated as a treatment for moderate to severe chronic asthma. In preclinical research, R256 has been shown to reduce airway inflammation and improve lung function.

19 Jun 2012

Bisphosphonate benefit for breast cancer yet to be proven

Older patients with breast cancer may benefit from adjuvant treatment with oral bisphosphonates, but further studies are needed before general application in the breast cancer population, say researchers.

19 Jun 2012